Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021

High Resolution Image Download MS PowerPoint Slide KRAS G12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS G12C, selective inhibition of KRAS G12D presents a significant challenge due to the requirement of inhibitors to bind KRAS G12D with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS G12D inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS G12D mutant xenograft mouse tumor model.

Cited by 737 works. doi:10.1021/acs.jmedchem.1c01688

Authors

References